Tendência nos gastos com medicamentos neuropsiquiátricos em Minas Gerais: Há aumento da oferta de antiparkinsonianos?

Translated title of the contribution: Spending trends on neuropsychiatric drugs in Minas Gerais: is the offer of anti-parkinson drugs increasing?

Liliany Mara Silva Carvalho, Jessica de Castro Alves, Tatiana Luz

Research output: Contribution to journalArticle


Introduction: Neuropsychiatric drugs are used for a wide variety of neurological and psychiatric conditions. Aims: To analyze the evolution and determinants of public spending on these medicines in Minas Gerais,2010 to 2017. Methods: Datathe Integrated Materials and Services Administration System (SIAD) database were used to estimate volumes of acquisition and expenses. Decomposition analysis was performed and, for anti-Parkinson drugs, the list of purchased drugs was analyzed and Drug Utilization technique (DU90%) was applied. Results: Annual expenditure decreased by 36%,R$ 111.7 million in 2010 to R$ 40.9 million in 2017, having as determinant factors the drops in prices and volume, associated with changes in the drug mix, that favored the acquisition of more expensive products, on average. The expenditure increase for anti-parkinsonians stands out, nonetheless, with significant change in the drug mix purchased. Conclusion: This study contributed to a better understanding of public spending on neuropsychiatric drugs. Reduction in volume can increase the risk of shortages. Regarding anti-parkinsonians, there is no evidence to suggest an increase in supply to the population.
Translated title of the contributionSpending trends on neuropsychiatric drugs in Minas Gerais: is the offer of anti-parkinson drugs increasing?
Original languageMultiple languages
JournalRevista Ciência & Saúde Coletiva
Early online date8 Jun 2020
Publication statusE-pub ahead of print - 8 Jun 2020


  • pharmaceutical services
  • drug costs
  • supply
  • central nervous system agents
  • antiparkinson agents

Cite this